Momenta, Mylan plan trial of biosimilar to Regeneron eye drug
(Reuters) - Momenta Pharmaceuticals Inc and Mylan NV plan to begin a pivotal clinical trial of a biosimilar to Regeneron Pharmaceuticals Inc's blockbuster eye drug Eylea in the first half of this year, the two companies said on Wednesday.
from Reuters: Health News http://reut.rs/2E2lKUx
http://bit.ly/2zwRqiM